Presymptomatic micro RNA targets for treatment of neurodegeneration pathology
AssigneeThe Trustees of Indiana University
InventorsSalil Sharma, Hui-Chen Lu
Life of this patent
Estimating the term…
Abstract
Compositions and methods are provided for the early detection of neuroinflammation in a patient in a presymptomatic stage of a neurodegenerative disease. The method comprises identifying patients with elevated expression levels of a micro RNA selected from the group consisting of miR142-3p, miR142-5p, miR181a, miR181b, miR219-3p and miR219-5p. The identified patients can then be treated with a therapeutic pharmaceutical composition comprising antimiR oligonucleotides.
Claims3
A method of treating neuroinflammation in a patient having a neurodegenerative condition and exhibiting elevated levels of two or more micro RNAs selected from the group consisting of miR142-3p, miR142-5p, and miR219-3p, said method comprising:
- identifying in patients having a neurodegenerative condition, those patients having elevated levels of two or more micro RNAs selected from the group consisting of miR219-3p, miR142-3p and miR142-5, by
- i) obtaining a reference expression level of two or more micro RNAs selected from the group consisting of miR219-3p, miR142-3p and miR142-5p;
- ii) determining an expression level of two or more micro RNAs selected from the group consisting of miR219-3p, miR142-3p and miR142-5p, and corresponding to those of step i), in a sample obtained from said patient having a neurodegenerative condition, wherein an increase in the expression level of said two or more micro RNAs selected from the group consisting of miR142-3p and miR142-5p in said patient's sample as compared to the reference expression level identifies the patient as having neuroinflammation;
- and
- administering to said patient having a neurodegenerative condition and identified as having elevated levels of said two or more micro RNAs selected from the group consisting of miR142-3p, miR142-5p, and miR219-3p a therapeutic composition comprising an antisense or interference oligonucleotide that is complementary to a micro RNA selected from the group consisting of miR142-3p, miR142-5p, and miR219-3p, wherein said antisense or interference oligonucleotide reduces the expression of a micro RNA selected from the group consisting of miR219-3p, miR142-3p and miR142-5p and provides treatment of said neuroinflammation.
A method of treating neuroinflammation in a patient with a neurodegenerative condition, said method comprising
- i) obtaining a reference expression level of miR142-3p and miR219-3p;
- ii) determining an expression level of miR142-3p and miR219-3p, in a sample obtained from said patient, wherein an increase in the expression level of miR142-3p and miR219-3p in said patient's sample as compared to the reference expression level identifies the patient as having neuroinflammation;
- and
- administering a therapeutic composition comprising antisense or interference oligonucleotides that are complementary to the sequence of miR142-3p and miR219-3p to reduce the expression of miR142-3p and miR219-3p and treat said neuroinflammation.
Dependencies are inferred from the claim text.